Unbiased Analysis of Today's Healthcare Issues

Archive for the 'Pharmaceuticals' Category

Predicting Real-World Effectiveness of Cancer Therapies Using OS and PFS Clinical Trials Endpoints

Clinical trials for cancer treatments aim to demonstrate whether one treatment is better than another. What is of most interest to patients, providers and payers, however, is which treatment works best in the real-world, not in a randomized controlled trial. Further, clinical trials often use progression free survival to measure treatment outcomes rather than overall […]

Read the rest of this entry »

Highlights from the 2017 ISPOR Conference

Over the past few days, I have been attending the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Annual Conference in Boston. The session had a number of interesting presentations. While I was not able to catch them all, below are links to a few highlights. Darius Lakdawalla, Defining and Measuring Value in Healthcare […]

Read the rest of this entry »

Will the UK become a “desert for healthcare innovation”?

That is the claim made by the Association of the British Pharmaceutical Industry (ABPI).  Lisa Anson, who took over as ABPI president last week, told The Times that the financial squeeze on the NHS threatened the whole of Britain’s £30 billion life sciences sector as firms would reconsider working in the UK.  ABPI asked for the […]

Read the rest of this entry »

FDA Hedges

Pharmaceutical companies face major risk.  There is risk that the drugs they are researching don’t work (e.g., lack of efficacy) or are not safe.  There is risk that health insurers or government payers will not cover their treatment.  And there is risk that the FDA will not approve a drug after a Phase III clinical trial. […]

Read the rest of this entry »

Applying Cost Effectiveness Analysis to all Health Care Interventions

That is the topic of a Health Affairs blog post published today by James Baumgarder and Peter Neumann.  An excerpt is below. Cost-effectiveness analysis (CEA) is an important tool for assessing and pointing the way toward better health care efficiency. The number of published CEAs on health care interventions has blossomed, averaging 34 per year […]

Read the rest of this entry »

Does drug detailing affect prescribing patterns?

The obvious answer seems to be ‘yes’.  Why would pharmaceutical companies spend billions of dollars on drug detailing (i.e., visits by pharmaceutical representatives to physicians to explain drug benefits) and drug samples if they don’t work?   When I say billions, I mean billions: A new study by Datta and Dave (2017), however, finds that drug […]

Read the rest of this entry »

Drug approval and reimbursement when clinical trials use surrogate endpoints

An interesting paper from some of my colleagues at Precision Health Economics: Approval of new drugs is increasingly reliant on “surrogate endpoints,” which correlate with but imperfectly predict clinical benefits. Proponents argue surrogate endpoints allow for faster approval, but critics charge they provide inadequate evidence. We develop an economic framework that addresses the value of […]

Read the rest of this entry »

How do payers use patient reported outcomes?

This is the question asked by a study conducted by Brogen et al. (2017).  To see how payers use patient reported outcomes (PRO) in oncology, the authors conducted a literatures search, and searched the websites of the following health technology assessment bodies: Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, Canadian Agency for Drugs and Technologies […]

Read the rest of this entry »

Which cancer treatment is best?

This seems like a straightforward question, but clearly depends on what you mean by “best”.  Some drugs will be more efficacious and have more adverse events; other drugs may be less efficacious but have fewer adverse events.  What if a one drug shows an 80% improvement in progression free survival (PFS), but a 50% improvement in overall […]

Read the rest of this entry »

How much money do drug companies get for their drugs?

Let’s say a you fill a 30-day prescription and the list price of the drug is $100.  Let’s say that you pay a $10 copay and your insurer pays $90.  What share of this $100, does the drug company receive. Most people would guess pretty close to $100, but a recent report by Aaron Vandervelde and […]

Read the rest of this entry »